ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2891

Loss Of Caspase 8 Exacerbates Dendritic Cell Activation In a MyD88- and RIPK1-Dependent Manner That Is Controlled By Inhibitory Molecules Transcribed By IRF3

Carla M. Cuda1, Alexander V. Misharin2, Rana Saber2 and Harris R. Perlman3, 1Medicine / Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, 2Medicine/Rheumatology, Northwestern University, Chicago, IL, 3Feinberg School of Medicine, Northwestern University, Chicago, IL

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: apoptosis and dendritic cells, Cell Signaling, SLE

  • Tweet
  • Email
  • Print
Session Information

Title: Systemic Lupus Erythematosus - Animal Models

Session Type: Abstract Submissions (ACR)

Background/Purpose: Previous studies implicate dendritic cells (DCs) in the initiation and persistence of systemic lupus erythematosus (SLE).  While DCs from SLE patients exhibit elevated activation, the factors responsible remain unknown.  To this end, we recently identified that caspase 8, an enzyme known to initiate apoptosis and/or suppress necroptosis (by inhibition of RIPK signaling) in a multitude of cells, is a novel DC-specific inhibitor of inflammatory processes independent of DC survival.

Methods: Mice lacking caspase 8 specifically in DCs were generated (CreCD11cCasp8flox/flox).  CreCD11cCasp8flox/flox mice were also crossed with MyD88flox/flox, IRF3-/- or IRF7-/- mice to determine the role of these molecules in disease development.  Flow cytometric analysis was used to characterize DC populations in mixed bone marrow chimeras and BrdU pulse assays.  Bone marrow derived DCs were cultured with TLR agonists +/- necrostatin-1 (RIPK1 inhibitor), 1MT (indoleamine 2,3-dioxygenase (IDO) inhibitor), zIETD-FMK (caspase 8 enzymatic inhibitor).  Luminex based assays detected cytokine and transcription factor DNA binding levels.  

Results: CreCD11cCasp8flox/flox develop a SLE-like disease characterized by splenomegaly, lymphadenopathy, autoantibodies, glomerulonephritis, immune complex deposition in the kidney, proteinuria, an interferon signature, and early mortality.  Loss of caspase 8 in DCs does not affect their survival, as there are equal numbers of CreCD11cCasp8flox/flox and WT DCs in mixed bone marrow chimeras, there is no change in DC turnover rate using BrdU pulse assays, and bone marrow derived DCs display similar levels of death independent of caspase 8 or RIPK1.  However, caspase 8-deficient DCs are highly activated, leading to lymphocyte hyperactivation in a paracrine manner.  Immune complexes containing self nucleic acids activate TLR7/9, which require the adaptor MyD88 for subsequent up-regulation of proinflammatory gene expression.  The increased activation of CreCD11cCasp8flox/flox DCs is controlled by a MyD88-dependent mechanism, as DC-specific loss of MyD88 in CreCD11cCasp8flox/flox mice reduces disease, and caspase 8 deficient DCs display a hyperresponsiveness to TLR7/9 ligation with increased DNA binding activity of IRF independent of caspase 8’s enzymatic activity.  Additionally, blocking RIPK1, but not IDO, signaling dampens TLR7/9 induced secretion of proinflammatory cytokines in caspase 8 deficient DCs.  Despite caspase 8’s known inhibitory role on IRF3 activity, deletion of IRF3, but not IRF7, in CreCD11cCasp8flox/flox mice exacerbates rather than ameliorates SLE-like disease, indicating that IRF3 transcribes inhibitory molecules that attempt to control the activation induced by the loss of caspase 8.

Conclusion: DC-specific loss of caspase 8 induces an SLE-like disease initiated by heightened DC activation via a MyD88- and RIPK1-dependent unknown mechanism.  This constitutive activation is dampened by IRF3-specific transcription of unknown molecules possessing inhibitory functions, thereby uncovering novel roles for caspase 8 and IRF3 and highlighting potentially useful targets for autoimmune disease therapy.


Disclosure:

C. M. Cuda,
None;

A. V. Misharin,
None;

R. Saber,
None;

H. R. Perlman,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/loss-of-caspase-8-exacerbates-dendritic-cell-activation-in-a-myd88-and-ripk1-dependent-manner-that-is-controlled-by-inhibitory-molecules-transcribed-by-irf3/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology